[AUPH] Aurinia Pharmaceuticals Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 99.78 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.18 Change: 0.03 (1.4%)
Ext. hours: 2.19 Change: 0.01 (0.46%)

chart AUPH

Refresh chart

Strongest Trends Summary For AUPH

AUPH is in the long-term up 125% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding32.29 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week7.64 Low 52 week4.53 Last close7.31 Last change-4.32%
RSI72.35 Average true range0.48 Beta0.77 Volume1.13 M
Simple moving average 20 days10.99% Simple moving average 50 days20.73% Simple moving average 200 days28.2%
Performance Data
Performance Week3.1% Performance Month21.63% Performance Quart26.91% Performance Half26.91%
Performance Year38.97% Performance Year-to-date7.18% Volatility daily4.15% Volatility weekly9.28%
Volatility monthly19.02% Volatility yearly65.87% Relative Volume859.31% Average Volume778.07 K
New High New Low

News

2019-03-19 22:14:56 | Aurinia Pharmaceuticals Inc AUPH Q4 2018 Earnings Conference Call Transcript

2019-03-19 16:14:33 | Aurinia: 4Q Earnings Snapshot

2019-03-19 16:02:00 | Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

2019-03-19 14:30:00 | Aurinia Pharmaceuticals Inc. to Host Earnings Call

2019-03-14 07:00:00 | Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease

2019-03-12 10:30:02 | Analysts Estimate Aurinia Pharmaceuticals AUPH to Report a Decline in Earnings: What to Look Out for

2019-03-07 16:05:00 | Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019

2019-02-27 11:39:23 | After Patent News, Aurinia Pharmaceuticals Still Has More to Prove

2019-02-27 06:30:00 | Aurinia Closes At-The-Market Facility

2019-02-26 13:28:31 | Big Pharma faces the Senate in drug price hearings

2019-02-25 16:16:00 | Here's Why Aurinia Pharmaceuticals' Stock Jumped Today

2019-02-25 07:00:00 | Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis

2019-02-20 16:01:00 | Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City

2019-01-30 14:33:21 | Is Aurinia Pharmaceuticals a Buy?

2019-01-30 08:10:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Leidos, Nomad Foods, Huron Consulting Group, Casella Waste, The Medicines, and Aurinia Pharmaceuticals — New Research Emphasizes Economic Growth

2019-01-22 09:09:32 | Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial

2019-01-22 07:00:00 | Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome

2019-01-21 16:49:00 | Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome

2019-01-21 08:45:01 | Do Options Traders Know Something About Aurinia Pharmaceuticals AUPH Stock We Don't?

2019-01-16 08:20:00 | My Rx for How to Buy Aurinia Pharmaceuticals on Its Breakout

2018-12-20 12:10:00 | 4 Pharma Stocks Getting a Boost on Thursday 12/20/18

2018-12-19 08:00:00 | Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco

2018-11-30 17:18:00 | Aurinia Establishes at-the-Market Facility

2018-11-27 08:00:00 | Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-09 07:00:00 | Aurinia to Participate in November Investor Conferences

2018-11-08 17:45:10 | Aurinia Pharmaceuticals AUPH Reports Q3 Loss, Tops Revenue Estimates

2018-11-08 16:39:29 | Aurinia: 3Q Earnings Snapshot

2018-11-08 16:02:00 | Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development

2018-10-25 07:00:00 | Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018

2018-10-16 08:55:00 | New Research: Key Drivers of Growth for Haverty Furniture Companies, BLACKLINE INC, MagnaChip Semiconductor, Kinross Gold, Aurinia Pharmaceuticals, and NEXEO SOLUTIONS — Factors of Influence, Major Initiatives and Sustained Production

2018-10-03 17:49:00 | Here's What Pushed Aurinia Pharmaceuticals Inc. Up 16.8% in September

2018-09-28 08:31:12 | Aurinia Pharmaceuticals AUPH in Focus: Stock Moves 6.7% Higher

2018-09-26 08:25:04 | The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

2018-09-25 16:01:00 | Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis

2018-09-19 16:01:00 | Aurinia to Participate in Upcoming Investor Conferences

2018-08-28 07:00:00 | Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

2018-08-17 07:35:00 | Investor Expectations to Drive Momentum within Natural Resource Partners LP, Insmed, MagnaChip Semiconductor, Changyou, Pain Therapeutics, and Aurinia Pharmaceuticals — Discovering Underlying Factors of Influence

2018-08-09 17:35:09 | Aurinia Pharmaceuticals AUPH Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 16:31:40 | Aurinia: 2Q Earnings Snapshot

2018-08-09 16:02:00 | Aurinia Reports Second Quarter Financial Results and Operational Highlights

2018-08-09 12:44:19 | Aurinia Pharmaceuticals Inc’s TSE:AUP Shift From Loss To Profit

2018-07-30 16:20:00 | Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018

2018-07-20 06:00:00 | 5 Favorite Biotech Bets

2018-07-14 15:47:00 | Here's Why Aurinia Pharmaceuticals Inc. Gained 32.2% in the First Half of 2018

2018-07-13 10:36:27 | Aurinia Pharmaceuticals Has Lots of Upside Potential

2018-07-12 08:37:18 | Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial

2018-07-11 16:01:00 | Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

2018-06-26 07:10:00 | Free Technical Reports on Array BioPharma and Three Additional Biotech Equities

2018-06-25 07:00:00 | Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin

2018-06-22 16:30:00 | Aurinia Announces Results of Annual General Meeting